Q-omics provides the consensus-scored ERHP2 profile across patient tissues and cancer cell-line models. ERHP2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ERHP2 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, ERHP2 RNA expression shows 4,762 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, THCA, and LSCC as cancer lineages where ERHP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERHP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERHP2 survival associations across molecular data types. ERHP2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERHP2 RNA expression–survival associations across cancer types. High ERHP2 expression shows unfavorable associations in BRCA, MESO, SKCM, LIHC, PAAD and OV. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ERHP2 RNA expression.
This table summarizes ERHP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ERHP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERHP2 shows lower tumor expression in THCA and higher tumor expression in LIHC. The THCA box plot shows higher ERHP2 RNA expression in normal versus tumor tissue (log2 FC = −0.042, t-test p < 0.001).
This table shows molecular features associated with ERHP2 in patient tissues and cancer cell lines. In patient samples, ERHP2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
